IN THE SPOTLIGHT

Disparities in Kidney Disease and the Race-Neutral eGFR - Research and Action in NYC’s Public Hospital System

Disparities in Kidney Disease and the Race-Neutral eGFR - Research and Action in NYC’s Public Hospital System

Case Report: SMARCA4-deficient non-small cell lung cancer - effective local control with radiotherapy and emergence of a targetable EGFR mutation

Case Report: SMARCA4-deficient non-small cell lung cancer - effective local control with radiotherapy and emergence of a targetable EGFR mutation

Risk of high-grade infections in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a meta-analysis of randomized controlled trials

Risk of high-grade infections in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a meta-analysis of randomized controlled trials

Greater Accuracy of the eGFR Formula by Using a Power Function of Patient Height over Its Unidimensional Value in Pediatric Kidney Transplantation

Greater Accuracy of the eGFR Formula by Using a Power Function of Patient Height over Its Unidimensional Value in Pediatric Kidney Transplantation

BRAFV600E patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data

BRAFV600E patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data

TAS3351 is a brain penetrable EGFR-TKI that overcomes T790M and C797S resistant mutations

TAS3351 is a brain penetrable EGFR-TKI that overcomes T790M and C797S resistant mutations

Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption

Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer

A predictive model for treatment efficacy in RAS wild-type advanced colorectal cancer: development and external validation for EGFR inhibitor plus anti-angiogenic therapy based on a retrospective cohort

A predictive model for treatment efficacy in RAS wild-type advanced colorectal cancer: development and external validation for EGFR inhibitor plus anti-angiogenic therapy based on a retrospective cohort